🇺🇸 FDA
Patent

US 12358896

LRRK2 inhibitors and methods of making and using thereof

granted A61PA61P25/16A61P25/28

Quick answer

US patent 12358896 (LRRK2 inhibitors and methods of making and using thereof) held by DENALI THERAPEUTICS INC. expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
DENALI THERAPEUTICS INC.
Grant date
Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P25/16, A61P25/28, A61P29/00, A61P35/00